



Ophthalmic



A CLEAR
VISION FOR
EYE CARE





One of the main criticisms of self-administered eye care treatments today is poor patient adherence, especially with chronic diseases.

We strive to improve the patient experience by providing safe and effective multidose eyedroppers for preservative-free solutions, used globally.

Our systems are predominantly used for chronic pathologies requiring long-term daily use of eye drops, such as glaucoma, dry eye disease (DED), conjunctivitis, and allergies.

GLAUCOMA

Glaucoma is a group of eye diseases which result in damage to the optic nerve and causes vision loss, being a leading cause of global irreversible blindness. There are approximately 80 million people worldwide with Glaucoma, around half of which is undiagnosed.

The number of people living with Glaucoma is expected to rise to over **111 million by 2040.**

DRY EYE DISEASE (DED)

Global prevalence of DED

5–50%

Dry Eye Disease (DED) is a common multifactorial disease of the ocular surface with loss of homeostasis of the tear film and ocular symptoms, such as irritation, redness, discharge, and easily fatigued eyes. It is estimated that 1.4 billion people live with DED and that number is growing in both young and old adults.

Our ophthalmic products

COMMERCIALLY AVAILABLE PRODUCT

Novelia®

Nemera has developed an innovative ophthalmic multidose device to avoid the need for preservatives in formulations. It is designed to avoid bacterial contamination over treatment duration.



IN DEVELOPMENT PLATFORM

e-Novelia

e-Novelia is the smart ophthalmic add-on which improves an already existing way of administering ophthalmic treatments, to improve patients' adherence.



Our services



**Integrated services
from device selection to
GMP manufacturing**



**Early-stage
Innovation**



**Testing services
for customer
formulations**

Novelia®

**0% preservatives,
100% eye protection!**

The Novelia® platform includes a broad range of configurations to accommodate all formulations.



Bottles (white and transparent)

- LDPE 5ml, 7.5ml, 11ml & 15ml (including soft versions)
- PP 11ml
- Novelia® BFS (Blow-Fill-Seal) allowing unique bottle shapes

Drop size

- Standard drop size: 40µl with water
- 5 additional drop sizes: (between 28µl and 46µl)

Flow control

- **PureFlow 10**
very liquid formulations
(viscosity 1-10cP)
- **PureFlow 200**
liquid formulations
(viscosity 10-200cP)
- **PureFlow 1500**
viscous formulations
(viscosity 200-1500cP)




Nemera has designed and developed a Vented Cap version which removes and dries the remaining liquid on the dropper tip.

HOW THE PUREFLOW™ TECHNOLOGY WORKS:

PureFlow technology guarantees integrity of the system.

The Novelia® device features a one-way valve that ensures that no contaminated liquid can be re-introduced into the container after a drop has been dispensed, completely removing the need to filter the liquid.

The intake of air into the dispenser takes place via a separate venting system with a silicone membrane referred to as PureFlow™ technology. This is a continuous barrier of homogeneous material which guarantees the integrity of the system.



Novelia® and PureFlow™ are trademarks of Nemera La Verpillière SAS.

The shape and color of the nozzle of Novelia dispenser and the shape of Novelia Vented Cap are protected by trademarks of Nemera La Verpillière SAS.

e-Novelia

The smart way to deliver eye drops.

e-Novelia, the smart ophthalmic add-on, improves an already existing way of administrating ophthalmic treatments, to improve patients' adherence.

Tile sensor and LED indication for device positioning

Remaining drug indicator

Drop detection

Location tracking

Electronic IFU

Treatment history and compliance

Handling Aid

Rechargeable

Shelf-life management



**Ergonomics and
user friendliness**



&



Nemera and Rommelag® have combined their advanced technologies and experiences to produce Novelia® processed by Blow-Fill-Insert-Seal (BFIS*)

Key Benefits of BFIS

- Advanced aseptic BFIS process according to US Pharmacopeia, FDA and GMP Guidelines
- Highest sterility assurance
- Ergonomic and easy to squeeze bottles
- Customized container designs for differentiated products
- Proven and cost-effective production

*BFIS is the term used in the in the guidelines (US Pharmacopeia, FDA and GMP Guidelines) / BFIS is a Rommelag term.

Our services

INTEGRATED SERVICES

from device selection to GMP manufacturing

We have developed end-to-end services and expertise in ophthalmic device development, and device consulting, to complement our diverse portfolio of products to help you through every step of the journey.



EARLY-STAGE INNOVATION

We provide a full understanding of the patient journey and recommends user-related activities to further optimize patients' experience for a specific drug/device combination product.

TESTING SERVICES FOR CUSTOMER FORMULATIONS

Thanks to our high-end laboratory facilities, we propose device plus formulation test services, as well as test methods development for our customers' needs.



Learn more about
our services at:
nemera.net/our-services

Our broad offering

Offering a broad range of solutions in major delivery routes, we are the holistic development and manufacturing partner for your custom drug delivery device solution.

PRODUCTS

Nemera proprietary drug delivery devices

Contract developed and manufactured drug delivery devices

SERVICES

From device selection to product lifecycle management

HOLISTIC END-TO-END CAPABILITIES

Research & development

Process engineering & Industrialization

Clinical & commercial Manufacturing